Affiliation:
1. From the Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston; and the Center for Professional Excellence, The Methodist Hospital, Houston, TX.
Abstract
AbstractProspective analysis of the importance of the plasma levels of β-2 microglobulin (B2M) in 553 patients with myelodysplastic syndrome (MDS) found that B2M is an independent prognostic variable for survival with weighted significance second only to the karyotype. The incorporation of the B2M covariate into risk assessment of MDS patients added significantly to the power of the IPSS to stratify MDS patients into risk categories. Our results further document that the 2 objectively measured covariates that display the highest power to predict survival, that is, karyotype and B2M, can alone be used for risk stratification. While the results must be verified in an independent and comparable population, our data strongly recommend routine measurement of B2M in patients with MDS.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference21 articles.
1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89: 2079-2088.
2. Schardijn GH, Statius van Eps LW. Beta 2-microglobulin: its significance in the evaluation of renal function. Kidney Int.1987;32: 635-641.
3. Gatto S, Onida F, Estey E, et al. Prognostic significance of serum beta-2-microglobulin levels in myelodysplastic syndromes [abstract 606]. Hematology J.2002;3(suppl 1): 182.
4. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol.1982;51: 189-199.
5. Beran M, Shen Y, Kantarjian H, et al. High-dose chemotherapy in high-risk myelodysplastic syndrome. Cancer.2001;92: 1999-2015.
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献